* Neuroone Medical Technologies Corp NMTC.OQ NMTC.O is
expected to show a rise in quarterly revenue when it reports
results on August 9 (estimated).
* The Eden Prairie Minnesota-based company is expected to
report
a 993.8% increase in revenue to $350 thousand from $32 thousand
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Neuroone Medical
Technologies Corp is for a loss of 20 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Neuroone
Medical
Technologies Corp is $2.63, above its last closing price
of $1.14.
This summary was machine generated August 7 at 12:11 GMT. All
figures in US dollars unless otherwise stated